(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-3.02% € 150.98
Live Chart Being Loaded With Signals
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection...
Stats | |
---|---|
Dagens volum | 1 121.00 |
Gjennomsnittsvolum | 714.00 |
Markedsverdi | 267.33B |
EPS | €0 ( 2024-04-26 ) |
Neste inntjeningsdato | ( €0 ) 2024-07-25 |
Last Dividend | €1.480 ( 2023-07-13 ) |
Next Dividend | €0 ( N/A ) |
P/E | 59.44 |
ATR14 | €0.887 (0.59%) |
Abbvie Inc Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Abbvie Inc Økonomi
Annual | 2023 |
Omsetning: | €54.32B |
Bruttogevinst: | €33.90B (62.42 %) |
EPS: | €2.75 |
FY | 2023 |
Omsetning: | €54.32B |
Bruttogevinst: | €33.90B (62.42 %) |
EPS: | €2.75 |
FY | 2022 |
Omsetning: | €58.05B |
Bruttogevinst: | €40.64B (70.00 %) |
EPS: | €6.69 |
FY | 2021 |
Omsetning: | €56.20B |
Bruttogevinst: | €38.75B (68.96 %) |
EPS: | €6.92 |
Financial Reports:
No articles found.
Abbvie Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.410 (N/A) |
€1.410 (N/A) |
€1.480 (N/A) |
€1.480 (N/A) |
€1.480 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.570 | 2016-07-13 |
Last Dividend | €1.480 | 2023-07-13 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | €24.73 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.02 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.62 | |
Div. Directional Score | 7.62 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GRM.DE | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
PSM.DE | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% | |
BOSS.DE | Ex Dividend Knight | 2023-05-10 | Annually | 0 | 0.00% | |
INH.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
SRB.DE | Ex Dividend Knight | 2023-11-09 | Quarterly | 0 | 0.00% | |
DAM.DE | Ex Dividend Junior | 2023-05-10 | Annually | 0 | 0.00% | |
LOM.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
47T.F | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% | |
UZU.DE | Ex Dividend Knight | 2023-05-17 | Annually | 0 | 0.00% | |
ENL.DE | Ex Dividend Knight | 2023-07-24 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0895 | 1.500 | 8.21 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0361 | 1.200 | 8.80 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.400 | 1.500 | 6.66 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 2.17 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.872 | 0.800 | -0.639 | -0.512 | [1 - 3] |
quickRatioTTM | 0.633 | 0.800 | -0.980 | -0.784 | [0.8 - 2.5] |
cashRatioTTM | 0.339 | 1.500 | 9.23 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.441 | -1.500 | 2.65 | -3.98 | [0 - 0.6] |
interestCoverageTTM | 3.35 | 1.000 | 9.87 | 9.87 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.93 | 2.00 | 5.69 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.49 | 2.00 | 3.75 | 7.51 | [0 - 20] |
debtEquityRatioTTM | 5.73 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.624 | 1.000 | 2.93 | 2.93 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.235 | 1.000 | 7.30 | 7.30 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.385 | 1.000 | 8.97 | 8.97 | [0.2 - 2] |
assetTurnoverTTM | 0.403 | 0.800 | -0.645 | -0.516 | [0.5 - 2] |
Total Score | 10.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 58.66 | 1.000 | 4.18 | 0 | [1 - 100] |
returnOnEquityTTM | 0.400 | 2.50 | 7.86 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.49 | 2.00 | 5.84 | 7.51 | [0 - 30] |
dividendYielPercentageTTM | 4.71 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.93 | 2.00 | 5.69 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.17 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -1.078 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.420 | 1.000 | 1.988 | 0 | [0.1 - 0.5] |
Total Score | 4.62 |
Abbvie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.